HP
XGN icon

Harbourvest Partners’s Exagen XGN Stock Holding History

Harbourvest Partners’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,982
Closed -$343K – 49
2020
Q4 		$343K Hold
25,982
– – 0.13% 21
2020
Q3 		$282K Hold
25,982
– – 0.1% 31
2020
Q2 		$322K Hold
25,982
– – 0.14% 24
2020
Q1 		$414K Buy
+25,982
New +$516K 0.2% 28

Other funds holding XGN

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbourvest Partners's XGN Position: Q1 2021 in Review

Harbourvest Partners sold out of Exagen (XGN) in Q1 2021, closing a stake of 25,982 shares — an estimated $343K sold.

Harbourvest Partners first reported a position in XGN in Q1 2020 and held it in 4 quarters. The position peaked at $414K in Q1 2020. 57 funds tracked by Wall St. Rank hold XGN as of Q1 2021.

  • Harbourvest Partners reported no remaining Exagen position as of Q1 2021 after selling out during the quarter.
  • Harbourvest Partners sold 25,982 Exagen shares in Q1 2021, an estimated $343K.
  • Harbourvest Partners first reported a position in Exagen in Q1 2020 and held it in 4 quarters.
  • Harbourvest Partners's Exagen position peaked at $414K in Q1 2020.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q1 2021.

Based on Harbourvest Partners's 13F filing for Q1 2021, filed 17 May 2021.